ObjectiveTo summarize the recent advances in the relationship between long non-coding RNA (LncRNA) and tumor autophagy, autophagy and drug resistance regulation.MethodsReviewed the relevant literatures at home and abroad, and reviewed the recent research progress of LncRNA regulation of autophagy to affect tumor resistance.ResultsDrug resistance was a common problem in the process of anti-tumor therapy. Autophagy played an important role in the process of tumor resistance as an important mechanism to maintain cell homeostasis. Abnormal regulation of LncRNA could contribute to the occurrence and development of tumors, and could also mediate the resistance of tumor cells to anti-tumor drugs by promoting or inhibiting autophagy.ConclusionsLncRNA can mediate tumor autophagy in a positive or negative direction, and autophagy is a " double-edged sword” for tumor resistance. LncRNA may improve tumor resistance to drugs by regulating autophagy.
ObjectiveTo investigate the role of non-coding RNA (ncRNA) in the proliferation, migration and metastasis of hepatocellular carcinoma (HCC) and the mechanism of HCC resistance to sorafenib.MethodThe literatures of ncRNA studies related to the incidence of HCC in recent years were reviewed, and the relationship between different ncRNAs and the proliferation, migration and metastasis of HCC was summarized, and the mechanism of sorafenib resistance in the HCC was analyzed from the perspective of ncRNA.ResultsThere were many kinds of ncRNAs, which were classified into the long ncRNA and short ncRNA according to their length. Currently, microRNA, which was widely studied, belonged to the short ncRNA. The regulation of the expressions of different microRNAs and long ncRNA could enhance or inhibit the signaling pathway of the producing HCC and played an important guiding role in the diagnosis and treatment of HCC. Meanwhile, the targeted regulation of this ncRNA could reverse the sorafenib resistance in the HCC.ConclusionsncRNA plays an important role in the pathogenesis of HCC and has become a potential target for the treatment of HCC. Targeted regulation of specific ncRNA expression could reverse sorafenib resistance in HCC.